TY - JOUR
T1 - Interaction of 1, 25-Dihydroxyvitamin-D3 with Keratinocytes and Fibroblasts from Skin of Normal Subjects and a Subject with Vitamin-D-Dependent Rickets, Type II
T2 - A Model for Study of the Mode of Action of 1, 25-Dihydroxyvitamin D3
AU - Clemens, Thomas L.
AU - Adams, John S.
AU - Horiuchi, Noboru
AU - Gilchrest, Barbara A.
AU - Cho, Hideo
AU - Tsuchiya, Yutaka
AU - Matsuo, Nobutake
AU - Suda, Tatsuo
AU - Holick, Michael F.
PY - 1983/4
Y1 - 1983/4
N2 - The binding of [3H]l, 25-dihydroxyvitamin D3 (1, 25-(OH)2-[3H]D3) was examined in the cytosol of epidermal keratinocytes and dermal fibroblasts grown from normal human skin. Both cell types contained macromolecules with high affinity for 1, 25-(OH)2D3, as demonstrated by sucrose density gradient centrifugation, saturation binding analysis, and DNA-cellulose chromatography. Scatchard analysis of cytosol binding of the hormone yielded affinity constants of 1.0 × 10-10 and 0.8 × 10-10 M and binding capacities of 6.4 and 8.7 fmol/mg protein for fibroblasts and keratinocytes, respectively. In parallel studies, binding of 1, 25-(OH)2-[3H]D3 was evaluated in the cytosol from keratinocytes and fibroblasts cultured from a skin biopsy of a patient with vitamin D-dependent rickets, type II (DDRII), an inheritable disorder characterized by extreme end-organ resistance to the action of 1, 25-(OH)2D3. Multiple analyses by sucrose density gradient or saturation binding assays failed to reveal specific saturable binding of hormone, suggesting that in this disease the lack of an effective cytosolic receptor protein may account for end-organ insensitivity to the hormone. To evaluate the responsiveness of fibroblasts to 1, 25-(OH)2D3, we studied the effect of 1, 25-(OH)2D3 on cell growth. 1, 25-(OH)2D3 (10-10-10-6 M) caused a dose-dependent inhibition of cell growth in receptor-positive normal fibroblasts, whereas these doses of hormone did not affect the growth of receptor-defective DDR-II cells. Hence, the presence of an effective cytosolic receptor in normal skin fibroblasts may be necessary for expression of the growth inhibitory effect of 1, 25-(OH)2D3.
AB - The binding of [3H]l, 25-dihydroxyvitamin D3 (1, 25-(OH)2-[3H]D3) was examined in the cytosol of epidermal keratinocytes and dermal fibroblasts grown from normal human skin. Both cell types contained macromolecules with high affinity for 1, 25-(OH)2D3, as demonstrated by sucrose density gradient centrifugation, saturation binding analysis, and DNA-cellulose chromatography. Scatchard analysis of cytosol binding of the hormone yielded affinity constants of 1.0 × 10-10 and 0.8 × 10-10 M and binding capacities of 6.4 and 8.7 fmol/mg protein for fibroblasts and keratinocytes, respectively. In parallel studies, binding of 1, 25-(OH)2-[3H]D3 was evaluated in the cytosol from keratinocytes and fibroblasts cultured from a skin biopsy of a patient with vitamin D-dependent rickets, type II (DDRII), an inheritable disorder characterized by extreme end-organ resistance to the action of 1, 25-(OH)2D3. Multiple analyses by sucrose density gradient or saturation binding assays failed to reveal specific saturable binding of hormone, suggesting that in this disease the lack of an effective cytosolic receptor protein may account for end-organ insensitivity to the hormone. To evaluate the responsiveness of fibroblasts to 1, 25-(OH)2D3, we studied the effect of 1, 25-(OH)2D3 on cell growth. 1, 25-(OH)2D3 (10-10-10-6 M) caused a dose-dependent inhibition of cell growth in receptor-positive normal fibroblasts, whereas these doses of hormone did not affect the growth of receptor-defective DDR-II cells. Hence, the presence of an effective cytosolic receptor in normal skin fibroblasts may be necessary for expression of the growth inhibitory effect of 1, 25-(OH)2D3.
UR - http://www.scopus.com/inward/record.url?scp=0020693205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020693205&partnerID=8YFLogxK
U2 - 10.1210/jcem-56-4-824
DO - 10.1210/jcem-56-4-824
M3 - Article
C2 - 6300167
AN - SCOPUS:0020693205
SN - 0021-972X
VL - 56
SP - 824
EP - 830
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 4
ER -